Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cascara sagrada laxatives

This article was originally published in The Tan Sheet

Executive Summary

CDER Ombudsman James Morrison should "intercede and facilitate" a meeting between AHPA, Division of OTC Drug Products to discuss data on cascara sagrada, trade group says in Sept. 12 letter. OTC division denied association's earlier request to discuss May 9 final rule classifying ingredient as Category II in OTC laxative products. AHPA also has asked FDA to stay rule's Nov. 5 effective date (1"The Tan Sheet" June 17, 2002, p. 7). Separate petition submitted by Arnall Golden & Gregory (Atlanta) requests that FDA withhold enforcement action against manufacturers of cascara sagrada laxatives pending publication of laxatives final monograph. Petition also suggests FDA could consider "imposing certain labeling restrictions relating to the product's use" to keep such laxatives on the market...

You may also be interested in...



Aloe Definition Clarification In Laxatives Final Rule Requested By AHPA, IASC

FDA's final rule on aloe and cascara sagrada does not properly distinguish between aloe used in OTC drug laxatives and aloe vera gel used in foods and dietary supplements, AHPA and the International Aloe Science Council say in a 1citizen petition

Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Topics

UsernamePublicRestriction

Register

PS094549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel